| Literature DB >> 35513809 |
Yan Zhao1, Yue Ma1, Chongbo Zhao2, Jiahong Lu2, Hong Jiang1, Yanpei Cao3, Yafang Xu4,5.
Abstract
BACKGROUND: A growing number of studies show that integrated health care provides comprehensive and continuous care to patients with hypertension or diabetes. However, there is still no consensus about the effect of integrated health care on patients with hypertension or diabetes. The objective of this study was to verify the effectiveness of integrated health care for patients with hypertension or diabetes by using a systematic review and meta-analysis.Entities:
Keywords: Diabetes; Hypertension; Integrated health care; Meta-analysis; Systematic review
Mesh:
Substances:
Year: 2022 PMID: 35513809 PMCID: PMC9074341 DOI: 10.1186/s12913-022-07838-1
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.908
Fig. 1Strategies and methods in integrated health care
Search strategies in PubMed
| Searches | Resultsa | Type | |
|---|---|---|---|
| #1 | Search: ((((((((Integrated Health Care[Title/Abstract]) OR (Home Care Services[Title/Abstract])) OR (Hospital-Based Home Care Services[Title/Abstract])) OR (Home Health Nursing[Title/Abstract])) OR (Home Nursing[Title/Abstract])) OR (Comprehensive Health Care[Title/Abstract])) OR (Patient Care Planning[Title/Abstract])) OR (Primary Health Care[Title/Abstract])) OR (Progressive Patient Care[Title/Abstract]) | 34,350 | ADVANCED |
| #2 | Search: (((((((((case management[Title/Abstract]) OR (individual care plans[Title/Abstract])) OR (patient-centred medical home[Title/Abstract])) OR (personal health budgets[Title/Abstract])) OR (chronic care model[Title/Abstract])) OR (models for elderly[Title/Abstract] AND frail[Title/Abstract])) OR (disease-specific[Title/Abstract])) OR (Kaiser Permanente[Title/Abstract])) OR (Veterans Health Administration[Title/Abstract])) OR (care in Basque country[Title/Abstract]) | 49,857 | ADVANCED |
| #3 | Search: ((Hypertension[Title/Abstract]) OR (Diabetes[Title/Abstract])) OR (Diabetes Mellitus[Title/Abstract]) | 866,706 | ADVANCED |
| #3 | #1 AND #2 AND #3 | 91 | ADVANCED |
a Deadline to 31 October 2020.
Fig. 2Flow of studies throughout the review
Characteristics of included randomized controlled trial studies (n = 16)
| Authors, years | Participants | Intervention | Intervention providers | Outcome measures | Duration | Conclusion |
|---|---|---|---|---|---|---|
Mattei da Silva, ÂT et al. 2020 [ Brazil | 94 patients with hypertension Experiment group: 1) Age: 49.4 ± 6.4 2) Size: 47 Control group: 1) Age: 49.2 ± 8.4 2) Size: 47 | Evidence-based guidelines and information; Timely reminder; Regular follow up; Individual care planning | Nurses | •SBP*, DBP* •BMI* | 12 months | The intervention group’s SBP*, DBP* and BMI* decreased significantly compared to those of the control group |
Kastarinen MJ et al. 2002 [ Finland | 587 patients with hypertension Experiment-group: 1) Age: 54.4 ± 10.1 2) Size: 304 Control-group: 1) Age: 54.2 ± 9.9 2) Size: 283 | Evidence-based guidelines and information; Regular follow up; Patients participate in effective programs | Physician and a nutritionist; Local public health nurses | •SBP*, DBP* •BMI* | 12 months | Significant reductions after 1 year both in SBP* and in DBP* were in favour of the intervention group. |
Aubert RE et al. 2017 [ America | 138 patients with diabetes Experiment-group: 1) Age: 53 (Interquartile range: 47–61) 2) Size: 71 Control-group: 1) Age: 54 (Interquartile range: 46–60) 2) Size: 67 | Evidence-based guidelines and information; Timely reminder; Regular follow up; Individual care planning; Patients participate in effective programs | a board-certified family medicine physician and an endocrinologist; Local public health nurses | •HbA1c* | 12 months | A significant decrease in HbA1c* in intervention group. |
Hurwitz B et al. 1993 [ British | 181 patients with diabetes Experiment-group: 1) Age: 62.0 ± 11.2 2) Size: 89 Control-group: 1) Age: 63.1 ± 8.6 2) Size: 92 | Evidence-based guidelines and information; Regular follow up; Timely reminder | General practitioners; Clinic doctors | •HbA1c* | 6 months | Decrease in HbA1c* in intervention group. |
Gao JL et al. 2015 [ China | 1204 patients with hypertension Experiment-group: 1) Age: 66.0 ± 9.3 2) Size: 600 Control-group: 1) Age: 67.1 ± 10.3 2) Size: 604 | Evidence-based guidelines and information; Regular follow up; Individual care planning; Patients participate in effective programs | General practitioners | •SBP*, DBP* •BMI* | 12 months | The average DBP* decrease in the intervention group was significantly greater than that in the control group. |
Hacihasanoğlu R et al. 2010 [ Turkey | 80 patients with hypertension Experiment-group: 1) Age: 56.92 ± 8.04 2) Size: 40 Control-group: 1) Age: 55.62 ± 8.46 2) Size: 40 | Evidence-based guidelines and information; Timely reminder; Regular follow up; Individual care planning; Patients participate in effective programs | Nurses | •SBP*, DBP* •BMI* | 12 months | A significant decrease in BP* in intervention group. |
Li YD et al. 2003 [ China | 415 patients with diabetes Experiment-group: 1) Age: 66.77 ± 7.29 2) Size: 215 Control-group: 1) Age: 67.95 ± 7.61 2) Size: 200 | Evidence-based guidelines and information; Regular follow up; Timely reminder; Patients participate in effective programs; Group visit | staff in general hospital; staff in community hospital | •HbA1c* | 12 months | A significant decrease in BP* and HbA1c* in the intervention group. |
Huang HL et al. 2019 [ China | 222 patients with diabetes Experiment-group: 1) Age: 68.3 ± 5.1 2) Size: 110 Control-group: 1) Age: 68.2 ± 5.4 2) Size: 112 | Evidence-based guidelines and information; Regular follow up; Individual care planning; Patients participate in effective programs | specialist physician general practitioner | •HbA1c* | 6 months 12 months | A significant decrease in BP* in the intervention group after 3, 6, and 12 months. A significant decrease in HbA1c* in intervention group after 6 months. |
Han Y et al. 2019 [ China | 100 patients with diabetes Experiment-group: 50 Control-group: 50 Age: 25 ~ 75 | Evidence-based guidelines and information; Regular follow up; Individual care planning | staff in general hospital; staff in community hospital | •HbA1c* | 6 months 12 months | A significant decrease in HbA1c* in the intervention group after 12 months. |
Gary TL et al. 2009 [ America | 488 patients with diabetes Experiment-group: 1) Age: 59 ± 11 2) Size: 235 Control-group: 1) Age: 56 ± 11 2) Size: 253 | Evidence-based guidelines and information; Timely reminder; Regular follow up; Individual care planning; Patients participate in effective programs | Nurses; Community health worker | •HbA1c* | 24 months | Those who had more visits with professional workers in intervention group had a statistically significant decline in HbA1c* level compared with the control group. |
Glasgow RE et al. 2005 [ America | 733 patients with diabetes Experiment-group: 1) Age: 62 ± 1.4 2) Size: 379 Control-group: 1) Age: 64 ± 1.3 2) Size: 354 | Evidence-based guidelines and information; Timely reminder; Regular follow up; Individual care planning; Patients participate in effective programs | Primary care physician; care manager | •HbA1c* | 12 months | Both conditions improved on measures of HbA1c*, but there was not a significant difference between conditions. |
Piatt GA et al. 2006 [ America | 73 patients with diabetes Experiment-group: 1) Age: 69.7 ± 10.7 2) Size: 27 Control-group: 1) Age: 68.6 ± 8.6 2) Size: 46 | Evidence-based guidelines and information; Timely reminder; Regular follow up; Individual care planning; Patients participate in effective programs | Physician; Nurses practitioners/physician assistants Behaviourist | •HbA1c* | 12 months | A marked decline in HbA1c* was observed in the intervention group but not in the control group. |
| Kong JXx et al. 2018 [ | 258 patients with diabetes Experiment-group: 1) Age: 69.12 ± 10.54 2) Size: 134 Control-group: 1) Age: 71.48 ± 8.79 2) Size: 124 | Evidence-based guidelines and information; Timely reminder; Regular follow up; Individual care planning; Patients participate in effective programs | Physicians | •HbA1c* | 9 months | The intervention group had a remarkable reduction in HbA1c*. |
Cicolini G et al. 2014 [ Italy | 298 patients with hypertension Experiment-group: 1) Age: 59.8 ± 15.0 2) Size: 100 Control-group: 1) Age: 58.3 ± 13.9 2) Size: 98 | Evidence-based guidelines and information; Regular follow up; Patients participate in effective programs | Nurses | •SBP*, DBP* •BMI* | 6 months | The intervention group showed a significantly greater improvement in BMI* and SBP* and DBP*. |
Beune EJ et al. 2014 [ Netherlands | 139 patients with hypertension Experiment-group: 1) Age: 53.3 ± 10.2 2) Size: 71 Control-group: 1) Age: 54.6 ± 9.5 2) Size: 68 | Individual care planning; Regular follow up; Patients participate in effective programs | Nurses | •SBP*, DBP* •BMI* | 6 months | In contrast to SBP* and BMI*, effect of the intervention on the between-group difference in DBP* reduction was significant. |
Leiva A et al. 2014 [ Spain | 208 patients with hypertension Experiment-group: 1) Age: 64.5 ± 9.8 2) Size: 103 Control-group: 1) Age: 66.7 ± 11.7 2) Size: 105 | Evidence-based guidelines and information; Timely reminder; Regular follow up; Family support; Patients participate in effective programs | Nurse | •SBP*, DBP* | 12 months | The SBP* in the intervention group was 151.3 versus 153.7 in the control group ( |
*BP Blood pressure, SBP Systolic blood pressure, DBP Diastolic blood pressure, BMI Body Mass Index, HbA1c Glycated haemoglobin.
Summary of the models
| Type of integration | Disease | Author | Model |
|---|---|---|---|
| Individual Model | Diabetes | Aubert RE et al.(2017) [ | Case management |
| Hurwitz B et al.(1993) [ | Patient-centred medical home | ||
| Gary TL et al.(2009) [ | Case management | ||
| Hypertension | Mattei da Silva, ÂT et al.(2020) [ | Case management | |
| Gao JL et al. (2015) [ | Patient-centred medical home | ||
| Hacihasanogu R et al.(2010) [ | Patient-centred medical home | ||
| Group-and disease-specific model | Diabetes | Li YD et al.(2003) [ | Disease-specific |
| Huang HL et al.(2019) [ | Disease-specific | ||
| Han Y et al.(2019) [ | Disease-specific | ||
| Glasgow RE et al.(2005) [ | Disease-specific | ||
| Piatt GA et al.(2006) [ | Chronic Care Model | ||
| Kong JX et al.(2018) [ | Chronic Care Model | ||
| Hypertension | Kastarinen MJ et al.(2002) [ | Disease-specific | |
| Cicolini G et al. (2014) [ | Disease-specific | ||
| Beune EJ et al. (2014) [ | Disease-specific | ||
| Leiva A et al. (2014) [ | Disease-specific |
Fig. 3Funnel plot for publication bias. a Funnel plot for SBP in the patients with hypertension. b Funnel plot for DBP in the patients with hypertension. c Funnel plot for HbA1c in the patients with diabetes. *SE: standard error; MD: mean difference; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated haemoglobin
Fig. 4Summaries of bias. * green = low risk of bias, red = high risk of bias, yellow = unclear risk of bias
Fig. 5Meta-analysis of SBP in patients with hypertension. a The meta-analysis of SBP in patients with hypertension. b The meta-analysis of SBP in patients involved in individual model. c The meta-analysis of SBP in patients involved in Group-and disease-specific model
Fig. 6Meta-analysis of DBP in patients with hypertension. a The meta-analysis of DBP in patients with hypertension. b The meta-analysis of DBP in patients involved in individual model. c The meta-analysis of DBP in patients involved in Group-and disease-specific model
Fig. 7Meta-analysis of BMI in patients with hypertension
Fig. 8Meta-analysis of HbA1c in patients with diabetes. a The meta-analysis of HbA1c in patients with hypertension. b The meta-analysis of HbA1c in patients involved in individual model. c The meta-analysis of HbA1c in patients involved in Group-and disease-specific model
Fig. 9The meta-analysis of HbA1c after 6 and 12 months of intervention. a The meta-analysis of HbA1c after 6-months intervention. b The meta-analysis of HbA1c after 6-months intervention